MedPath

Trastuzumab incombination with S-1/CDDP of HER2-positive advanced gastric cancer: a phase II trial.

Not Applicable
Conditions
HER2 positive gastric cancer
Registration Number
JPRN-UMIN000005792
Lead Sponsor
Dept. of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
30
Inclusion Criteria

Not provided

Exclusion Criteria

1. patient who has drug allergy as past history 2. case of administration contraindication 3. patient who needs flucytosine, phenytoin, and Warfarin 4. patient who has active infectious disease with fever over 38 degree 5. patient who has severe complication (intestinal palsy, ileus, interstitial pneumonia, DM, renal failure, liver failure under bad control) 6. patient who has heart disease(CHF, old MI, IHD, arrhythmia, and a valvular disease of the heart) 7. patient who has metastatic brain tumor with symptoms 8. watery diarrhea 9. severe ascites and/or pleural effusion 10. patient who has active double cancer 11. patient who want to be pregnant and /or pregnant woman 12. man who want to have a child 13. patient who was not judged to be suitable for this clinical trial

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
one year survival rate
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath